DK1071805T3 - Adenovirusvektorer til sygdomsbehandling - Google Patents

Adenovirusvektorer til sygdomsbehandling

Info

Publication number
DK1071805T3
DK1071805T3 DK99918712.3T DK99918712T DK1071805T3 DK 1071805 T3 DK1071805 T3 DK 1071805T3 DK 99918712 T DK99918712 T DK 99918712T DK 1071805 T3 DK1071805 T3 DK 1071805T3
Authority
DK
Denmark
Prior art keywords
gene
adenoviral
disease treatment
adenovirus vectors
expression
Prior art date
Application number
DK99918712.3T
Other languages
English (en)
Inventor
Lynda K Hawkins
Leisa Johnson
Terry Hermiston
Original Assignee
Onyx Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyx Pharma Inc filed Critical Onyx Pharma Inc
Application granted granted Critical
Publication of DK1071805T3 publication Critical patent/DK1071805T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/50Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001Cytosine deaminase (3.5.4.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK99918712.3T 1998-04-24 1999-04-19 Adenovirusvektorer til sygdomsbehandling DK1071805T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8303398P 1998-04-24 1998-04-24
US11710399P 1999-01-25 1999-01-25
PCT/US1999/008656 WO1999055831A2 (en) 1998-04-24 1999-04-19 Adenoviral vectors for treating disease

Publications (1)

Publication Number Publication Date
DK1071805T3 true DK1071805T3 (da) 2011-09-26

Family

ID=26768867

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99918712.3T DK1071805T3 (da) 1998-04-24 1999-04-19 Adenovirusvektorer til sygdomsbehandling

Country Status (10)

Country Link
EP (1) EP1071805B1 (da)
JP (1) JP2002512785A (da)
CN (1) CN1298451A (da)
AT (1) ATE517999T1 (da)
AU (1) AU772963B2 (da)
CA (1) CA2323235A1 (da)
CY (1) CY1111931T1 (da)
DK (1) DK1071805T3 (da)
PT (1) PT1071805E (da)
WO (1) WO1999055831A2 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002540A2 (en) * 1999-07-02 2001-01-11 Onyx Pharmaceuticals, Inc. Adenoviral vectors for treating disease
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
IL152423A0 (en) 2001-02-23 2003-05-29 Novartis Ag Novel vector constructs
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
CN100361710C (zh) * 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
CN1328372C (zh) * 2005-05-25 2007-07-25 上海希元生物技术有限公司 肿瘤靶向基因-病毒zd55-il-24及其构建方法和应用
US8865182B2 (en) * 2009-07-31 2014-10-21 Paxvax, Inc. Adenoviral-based vectors
CN102174479B (zh) * 2011-03-02 2013-04-03 北京锤特生物科技有限公司 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用
US9404090B2 (en) 2011-11-24 2016-08-02 Viromed Co., Ltd. Adenovirus producing novel cell line and the use thereof
CN105246337B (zh) * 2013-03-14 2019-02-15 吉恩维沃公司 用于基因治疗应用的胸苷激酶诊断分析
WO2018218240A1 (en) * 2017-05-26 2018-11-29 Epicentrx, Inc. Recombinant adenoviruses carrying transgenes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US6780406B1 (en) * 1994-03-21 2004-08-24 The Regents Of The University Of Michigan Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene

Also Published As

Publication number Publication date
AU3656399A (en) 1999-11-16
CA2323235A1 (en) 1999-11-04
PT1071805E (pt) 2011-10-04
EP1071805B1 (en) 2011-07-27
AU772963B2 (en) 2004-05-13
JP2002512785A (ja) 2002-05-08
ATE517999T1 (de) 2011-08-15
WO1999055831A3 (en) 2000-03-30
EP1071805A2 (en) 2001-01-31
CY1111931T1 (el) 2015-11-04
CN1298451A (zh) 2001-06-06
WO1999055831A2 (en) 1999-11-04

Similar Documents

Publication Publication Date Title
CY1111931T1 (el) Φορεις αδενοϊων για την αγωγη νοσου
Nawroz et al. Allelotype of head and neck squamous cell carcinoma
WO1999035170A8 (en) Compositions and methods for the treatment of tumor
DE69619110D1 (de) Adenovirale vektoren für die gentherapie
RU96112150A (ru) Рекомбинантный аденовирусный вектор и способы его применения
ES2151310T3 (es) Nuevas lineas celulares de complementacion para vectores adenovirales defectivos.
HUP0301318A2 (hu) Replikáció-defektív rekombináns adenovírus mutáns fő késői promóterrel
DK1623990T3 (da) Sammensætninger og fremgangsmåder til tumorbehandling
DK0797676T3 (da) Rekombinant adenoviral vektor og fremgangsmåder til anvendelse deraf
Lin et al. Myopodin, a synaptopodin homologue, is frequently deleted in invasive prostate cancers
EP1657256A3 (en) Compositions and methods for the treatment of tumor
WO2003032813A3 (en) Methods for the treatment of carcinoma
JP2004536572A5 (da)
Choi et al. Alterations of c-fos gene methylation in the processes of aging and tumorigenesis in human liver
ATE488529T1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
EP1100825A4 (en) MINK HUMAN GENE MUTATIONS ASSOCIATED WITH ARRHYTHMIA
WO2001002540A3 (en) Adenoviral vectors for treating disease
EP1642907A3 (en) Composition and methods for the diagnosis of tumours
Nomoto et al. Structural basis for the regulation of UDP-N-acetyl-α-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 gene expression in adenocarcinoma cells
WO2004075835A3 (en) Methods for the treatment of renal cell carcinoma
Hussein et al. Building bridges in cancer: mismatch repair and microsatellite instability
Fogt et al. Collecting duct carcinomas of the kidney: a comparative loss of heterozygosity study with clear cell renal cell carcinoma.
WO2000022136A3 (en) Recombinant e1a deleted adenoviral vectors
UA70909C2 (uk) Рекомбінантний аденовірусний вектор, фармацевтична композиція, що його містить, та набір для зменшення проліферації пухлинних клітин
DK1135514T3 (da) E1b-deleteret adenovirale shuttle-vektorer